Editor of Patient Care Online.
Blood-Based DNA Test for Colorectal Cancer: Daily Dose
Your daily dose of the clinical news you may have missed.
Remission from Type 2 Diabetes via Lifestyle Intervention Reduces Risk for CVD, CKD
Longer duration of remission was associated with a greater reduction in CKD and CVD risk, according to a post hoc analysis of the Look AHEAD study.
COVID-19 Vaccines Reduce Risk of Cardiac, Thromboembolic Outcomes: Daily Dose
Bempedoic Acid Associated with Reduced CV Risk in Statin-Intolerant Individuals Regardless of Ethnicity
ACC.24: Data from an analysis of the CLEAR Outcomes trial showed bempedoic acid was well-tolerated and reduced CV events in Hispanic/Latinx and non-Hispanic/Latinx participants.
Self-Administered Flu Vaccine May be “Powerful Tool” in Immunization Efforts, Says Expert
Ravi Jhaveri, MD, provides an overview of AstraZeneca's FluMist Quadrivalent vaccine and discusses why it could help increase vaccination rates.
New Data Shed Light on Disparities in Coronary Artery Calcium Screening
ACC.24: Findings showed a disproportionate distribution of CAC screening that favors White, educated, affluent, English-speaking individuals.
Tapinarof Cream 1.0% Effective for Atopic Dermatitis: Daily Dose
Obesity and Venous Disease: Risk Factors and Key Diagnostic Challenges
Johnson & Johnson Submits sBLA for Approval of Guselkumab for Adults with Ulcerative Colitis
Submission based on results from the phase 3 QUASAR induction study, which showed statistically significant and clinically meaningful improvements in symptoms.
COVID-19 Vaccines Reduce Risk of Cardiac, Thromboembolic Outcomes for up to 1 Year, According to New Data
New research highlights another benefit of COVID-19 vaccination, reported researchers.
Stroke Risk Mitigated by Low Levels of Exercise: Daily Dose
Aspirin Use among Older Adults: Daily Dose
Topline Phase 3 Data Released for Elinzanetant Efficacy for Moderate-to-Severe VMS
The novel dual NK-1,3 receptor antagonist demonstrated statistically significant reduction in the frequency of moderate-to-severe VMS vs placebo.
Underrepresentation of Patients with CKD in CVD Medication Trials: Daily Dose
Obesity and Venous Disease: An Expert Discussion
Shagun Bindlish, MD, board member of the American Diabetes Association, discusses a recent clinical practice statement she coauthored published in the journal Obesity Pillars.
Nirsevimab Effective Against RSV Hospitalization among Infants: Daily Dose
Dyslipidemia in American Indian Youth: Daily Dose
Plastic Debris in Carotid Plaque Linked to CV Events: Daily Dose
Aspirin Use among Older Adults Inconsistent with Current Guidelines, According to New Survey
In a survey of adults aged 50-80 years, 57% of those who reported taking aspirin regularly said they do not have a history of CVD.
In Pregnant Women with T1D, Higher Time-in-Range Improves Maternal, Neonatal Outcomes: Daily Dose
First Issue of Patient Care Online Digital Edition Goes Live
The inaugural digital issue of Patient Care focuses on the antiobesity and type 2 diabetes medications, semaglutide and tirzepatide.
Early Detection of CKD Progression in Primary Care: Daily Dose
Nirsevimab 90% Effective Against RSV Hospitalization among Infants, According to New CDC Data
Findings support current CDC recommendations that all infants should be protected by maternal RSV vaccination or infant receipt of nirsevimab.
Semaglutide Lowers CKD-Related Events in Persons with T2D, CKD: Daily Dose
New Data Show High Prevalence of Dyslipidemia in American Indian Youth
Few participants with dyslipidemia received lipid-lowering medications despite high prevalence, reported authors of the Strong Family Heart Study.
Migraine, Persistent VMS Tied to Higher Risk of CVD, Stroke: Daily Dose
Plastic Debris Detected in Carotid Plaque Linked to Higher Risk for MI, Stroke, Death
Patients who had microplastics and nanoplastics in their carotid plaque were at more than a fourfold risk for MI, stroke, or death compared to those who did not, according to a new study.
Neffy May be Safe, Effective for Treatment of Urticaria Flares: Daily Dose
Semaglutide Shows Potential for Significant CVD Prevention: Daily Dose
CDC: Persons with COVID-19, Flu, RSV, Other Respiratory Viruses No Longer Have to Isolate for 5 Days
The updated guidelines reflect the progress made in protecting against severe illness from COVID-19, said CDC Director Mandy Cohen, MD, MPH.